prnasiaJuly 20, 2020
Tag: Biopharma Initiates , CBP-201 , Moderate-to-Severe Atopic Dermatitis
July 20,2020
Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules, today announced that the first patient has been dosed in a Phase 2 clinical trial of CBP-201 for the treatment of moderate-to-severe atopic dermatitis (AD) in adult subjects. CBP-201 is a novel IL-4Rα antibody that, in a Phase 1b trial, demonstrated an efficacy profile superior to data from clinical studies of the current standard of care therapy for AD after four weeks of treatment.
"The eczematous skin lesions, itching, localized pain, and sleep disturbances associated with AD can interfere with a patient's ability to engage in physical, social and other routine daily activities," said Brian Feinstein, DO, a Board-certified dermatologist, consultant at Encore Research in Hollywood, Florida, and the first investigator to treat a patient in the Phase 2 study. "Moderate-to-severe disease accounts for about thirty percent of all AD cases. Of these patients, those who do not respond to corticosteroids have few options. The Phase 1b data for CBP-201 are promising and the Phase 2 study initiated today should provide insight as to the potential role it may play in improving overall care and outcomes for patients with moderate-to-severe AD."
In January 2020, Connect Biopharma reported topline results from the Phase 1b trial of CBP-201. These results demonstrated that CBP-201 treatment resulted in rapid improvement in skin lesions as measured by change from baseline in EASI on Day 29, with 42.9% and 50.0% of patients receiving 300 mg or 150 mg of CBP-201, respectively, achieving "clear/almost clear" skin, defined as a score of 0 or 1 in the Investigator's Global Assessment (IGA) scores, the primary efficacy endpoint required for FDA approval, compared, with 12.5% in the placebo group. The trial also demonstrated that skin lesion improvements were evidenced as early as one week after dosing of CBP-201 and were correlated with a rapid reduction in pruritus intensity and frequency, and that CBP-201 was also well tolerated.
"We believe that CBP-201 has best-in-class potential in the treatment of moderate-to-severe AD and are optimistic that the results of this Phase 2 trial will further differentiate CBP-201 from competitors," said Zheng Wei, PhD, Co-founder and CEO at Connect Biopharma. "IL-4Rα is a validated target for dupilumab, an FDA-approved therapy for the treatment of AD, but unmet medical need remains, with the majority of patients not achieving 'clear or almost clear' skin even after 16 weeks of treatment. Data from our Phase 1b trial suggest that CBP-201 has the potential to provide superior efficacy in AD with faster onset of action, and less frequent dosing compared with dupilumab."
The randomized, double-blind, placebo-controlled Phase 2 clinical trial is expected to enroll approximately 220 adults (ages 18 to 75 years) with moderate-to-severe AD across approximately 60 clinical sites in the United States, Australia, New Zealand, China, Europe and the UK. Subjects will be randomized (1:1:1:1) to one of three CBP-201 dosing regimens or placebo administered by subcutaneous injection. Subjects will be treated over 16 weeks and followed for an additional eight weeks following the last dose. The primary objective of the trial is to assess the efficacy of the various dosing schedules in this patient population; secondary objectives are to assess the safety and tolerability and to characterize the steady-state pharmacokinetic profile of the various dosing schedules. Study results are expected in the second half of 2021.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: